GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (FRA:4QK) » Definitions » Shiller PE Ratio

Codexis (FRA:4QK) Shiller PE Ratio : (As of May. 03, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Codexis Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Codexis Shiller PE Ratio Historical Data

The historical data trend for Codexis's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codexis Shiller PE Ratio Chart

Codexis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Codexis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Codexis's Shiller PE Ratio

For the Biotechnology subindustry, Codexis's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Codexis's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codexis's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Codexis's Shiller PE Ratio falls into.


;
;

Codexis Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Codexis's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Codexis's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.124/133.1571*133.1571
=-0.124

Current CPI (Dec. 2024) = 133.1571.

Codexis Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.129 99.621 -0.172
201506 -0.125 100.684 -0.165
201509 0.116 100.392 0.154
201512 -0.046 99.792 -0.061
201603 -0.153 100.470 -0.203
201606 0.045 101.688 0.059
201609 0.027 101.861 0.035
201612 -0.123 101.863 -0.161
201703 -0.168 102.862 -0.217
201706 -0.116 103.349 -0.149
201709 -0.176 104.136 -0.225
201712 0.017 104.011 0.022
201803 -0.081 105.290 -0.102
201806 -0.060 106.317 -0.075
201809 -0.034 106.507 -0.043
201812 -0.009 105.998 -0.011
201903 -0.080 107.251 -0.099
201906 -0.106 108.070 -0.131
201909 0.009 108.329 0.011
201912 -0.009 108.420 -0.011
202003 -0.118 108.902 -0.144
202006 -0.098 108.767 -0.120
202009 -0.085 109.815 -0.103
202012 -0.049 109.897 -0.059
202103 -0.118 111.754 -0.141
202106 -0.058 114.631 -0.067
202109 0.026 115.734 0.030
202112 -0.142 117.630 -0.161
202203 -0.118 121.301 -0.130
202206 -0.038 125.017 -0.040
202209 -0.152 125.227 -0.162
202212 -0.179 125.222 -0.190
202303 -0.318 127.348 -0.333
202306 -0.157 128.729 -0.162
202309 -0.469 129.860 -0.481
202312 -0.092 129.419 -0.095
202403 -0.147 131.776 -0.149
202406 -0.297 132.554 -0.298
202409 -0.261 133.029 -0.261
202412 -0.124 133.157 -0.124

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Codexis  (FRA:4QK) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Codexis Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Codexis's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Codexis Business Description

Traded in Other Exchanges
Address
200 Penobscot Drive, Redwood City, CA, USA, 94063
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Codexis Headlines

No Headlines